

2. A pharmaceutical composition in unit dosage form suitable for oral administration in the treatment of migraine headache, comprising:

- (a) metoclopramide in an amount effective to increase gastric motility in a patient; and
- (b) a non-acidic NSAID in an amount effective to reduce or eliminate pain associated with said migraine headache.

3. The pharmaceutical composition of claim 2, wherein said NSAID is a long acting NSAID.

4. The pharmaceutical composition of claim 2, wherein said NSAID is a cyclooxygenase-2 inhibitor.

5. A pharmaceutical composition in unit dosage form suitable for oral administration to a human for the treatment of migraine headache, comprising: metoclopramide and naproxen, present in an amount such that the combination is effective in reducing or eliminating pain associated with said migraine headache and wherein said dosage form is an acid-base storage stabilized dosage form.

6. A pharmaceutical composition in unit dosage form suitable for oral administration to a human for the treatment of migraine headache, comprising: metoclopramide and an analgesic, present in an amount such that the combination is effective in reducing or eliminating pain associated with said migraine headache and wherein said dosage form is coordinated.

7. The pharmaceutical composition of claim 6, wherein said unit dosage form is a tablet or capsule.

8. The pharmaceutical composition of claim 7, wherein said metoclopramide and said analgesic are in separate layers of a multilayer tablet.

9. The pharmaceutical composition of claim 6, wherein said unit dosage form is substantially free from any 5 HT agonist vasoactive agent.

10. The pharmaceutical composition of claim 6, wherein said analgesic is an NSAID.

11. The pharmaceutical composition of claim 10, wherein said NSAID is selected from the group consisting of: acetaminophen; ibuprofen; flurbiprofen; ketoprofen; naproxen; oxaprozin; etodolac; indomethacin; ketorolac; nabumetane; piroxicam; celecoxib; rofecoxib; meloxicam; JTE-522; L-745,337; and NS398; or a pharmaceutically acceptable salt thereof.

12. The pharmaceutical composition of claim 11, wherein said NSAID is naproxen.

13. The pharmaceutical composition of claim 10, wherein said NSAID is long acting or is formulated to be long acting.

14. A method of increasing the rate of absorption of a drug into the bloodstream of a patient, wherein rate of absorption is the time from which the drug is administered until the time that it reaches a peak plasma concentration, comprising:

administering said drug together with metoclopramide in a coordinated dosage form, wherein said metoclopramide is administered in an amount effective to increase gastric motility and wherein said drug is administered in a therapeutically effective amount.

15. The method of claim 14, wherein said patient is in a state of gastric stasis at the time said drug and said metoclopramide are administered.

16. The method of claim 14, wherein said drug is administered for the treatment of migraine headache.

17. The method of claim 14, wherein said drug is an analgesic.

18. The method of claim 14, wherein said drug is an NSAID.

19. The method of claim 18, wherein said NSAID is long acting or is formulated to be long acting.

20. The method of claim 18, wherein said NSAID is selected from the group consisting of: acetaminophen; ibuprofen; flurbiprofen; ketoprofen; naproxen; oxaprozin; etodolac; indomethacin; ketorolac; nabumetane; piroxicam; celecoxib; rofecoxib; meloxicam; JTE-522; L-745,337; and NS398; or a pharmaceutically acceptable salt thereof.

21. The method of claim 20, wherein said NSAID is naproxen.

22. A pharmaceutical composition in unit dosage form suitable for oral administration in the treatment of migraine headache, comprising:

- (a) metoclopramide in an amount effective to increase gastric motility in a patient; and
- (b) a non-acidic analgesic in an amount effective to reduce or eliminate pain associated with said migraine headache;

and wherein said unit dosage form is coordinated.

23. The pharmaceutical composition of claim 22, wherein said unit dosage form is a tablet or capsule.

24. The pharmaceutical composition of claim 22, wherein said unit dosage form is substantially free of any 5 HT agonist vasoactive agent.

25. The pharmaceutical composition of claim 22, wherein said analgesic is a long acting NSAID.

26. The pharmaceutical composition of claim 22, wherein said analgesic is a cyclooxygenase-2 inhibitor.

27. The pharmaceutical composition of claim 26, wherein said cyclooxygenase-2 inhibitor is celecoxib.

28. The pharmaceutical composition of claim 27, wherein said celecoxib is present in an amount of between 25 and 250 mg and said metoclopramide is present in an amount of between 1 mg and 100 mg.

29. The pharmaceutical composition of claim 22, wherein said analgesic is formulated to be long acting.

30. A pharmaceutical composition in unit dosage form suitable for oral administration in the treatment of migraine headache, comprising:

- (a) metoclopramide in an amount effective to increase gastric motility in a patient; and
- (b) a non-acidic analgesic in an amount effective to reduce or eliminate pain associated with said migraine headache;

and wherein said non-acidic analgesic is celecoxib.

31. The pharmaceutical composition of claim 30, wherein said celecoxib is present in an amount of between 25 and 250 mg and said metoclopramide is present in an amount of between 1 mg and 100 mg.

32. The pharmaceutical composition of either claim 30 or claim 31, wherein said unit dosage form is a tablet or capsule.

33. The pharmaceutical composition of either claim 30 or claim 31, wherein said unit dosage form is substantially free of any 5 HT agonist vasoactive agent.

34. A pharmaceutical composition in unit dosage form suitable for oral administration to a human for the treatment of migraine headache, comprising: metoclopramide and an analgesic, present in an amount such that the combination is effective in reducing or eliminating pain associated with said migraine headache and wherein said dosage form is an acid-base storage stabilized dosage form in which said metoclopramide and said analgesic are each in separate layers of a multilayer tablet.

35. A pharmaceutical composition in unit dosage form suitable for oral administration to a human for the treatment of migraine headache, comprising: metoclopramide and an analgesic, present in an amount such that the combination is effective in reducing or eliminating pain associated with said

US 6,479,551 B1

21

migraine headache, wherein said dosage form is an acid-base storage stabilized dosage form and wherein said unit dosage form is coordinated.

36. The pharmaceutical composition of either claim 34 or 35, wherein either said metoclopramide or said analgesic is 5 barrier coated.

37. The pharmaceutical composition of either claim 34 or 35, wherein said unit dosage form is substantially free of any 5 HT agonist vasoactive agent.

38. The pharmaceutical composition of either claim 34 or 35, wherein said analgesic is an NSAID.

39. The pharmaceutical composition of claim 38, wherein said NSAID is selected from the group consisting of:

22

acetaminophen; ibuprofen; flurbiprofen; ketoprofen; naproxen; oxaprozin; etodolac; indomethacin; ketorolac; nabumetane; piroxicam; celecoxib; rofecoxib; meloxicam; JTE-522; L-745,337; and NS398; or a pharmaceutically acceptable salt thereof.

40. The pharmaceutical composition of claim 39, wherein said NSAID is naproxen.

41. The pharmaceutical composition of claim 38, wherein said NSAID is long acting or is formulated to be long acting.

* * * * *